<DOC>
	<DOC>NCT01598090</DOC>
	<brief_summary>The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.</brief_summary>
	<brief_title>Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir</brief_title>
	<detailed_description>Data Monitoring Committee appointed for Part B Masking: Part A: Open Label Part B: Double Blind</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Chronic hepatitis C genotype 1. GT1b Capped at 50 % of naïve subjects Naives to prior antiHCV therapy [Interferon (IFN) and direct antiviral agent (DAA) based] Relapsers (defined as subjects who had undetectable HCV ribonucleic acid (RNA) on prior treatment regimen of alfa2a/RBV and Hepatitis C Virus (HCV) RNA &gt; 25IU/mL after discontinuation of treatment). Capped at 20% HCV RNA ≥ 100,000 IU/mL Subjects with compensated cirrhosis can be enrolled and will be capped at approximately 10% Seronegative for human immunodeficiency virus (HIV) and hepatitis B surface antigen (HBsAg) Men or women, 1870 years of age Chronic liver disease due to causes other than chronic HCV Current or past evidence of decompensation Conditions that preclude the use of Alfa/RBV/TVR per respective labels Diagnosed or suspected hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>